Last reviewed · How we verify
ANG003
At a glance
| Generic name | ANG003 |
|---|---|
| Also known as | Dose Level 1, Dose Level 2, Dose Level 3, and Dose Level 4. |
| Sponsor | Anagram Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Study to Assess the Safety and Efficacy of ANG003 (PHASE2)
- Phase 1 Study to Assess Safety and Efficacy of ANG003 (PHASE1)
- Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ANG003 CI brief — competitive landscape report
- ANG003 updates RSS · CI watch RSS
- Anagram Therapeutics, Inc. portfolio CI